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Abstract
Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the
treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib,
a second generation PI, with panobinostat, a HDACi, to determine the maximum tolerated dose (MTD) of the
combination (CarPan) and assess safety and efficacy among RRMM patients. Thirty-two patients (median of 4 prior
lines of therapy) were enrolled. The MTD was carfilzomib 36 mg/m2 (on days 1, 2, 8, 9, 15, and 16) and panobinostat
20 mg (TIW, 3 weeks on/1 week off, every 28 days), administered until progression. At the MTD, the most common
grade 3/4, treatment-related adverse events were thrombocytopenia (41%), fatigue (17%), and nausea/vomiting (12%).
The objective response rate (ORR) and clinical benefit rate were 63% and 68%, respectively. Median progression-free
survival (PFS) and overall survival (OS) for the entire population were 8 and 23 months, respectively. No differences in
terms of ORR (55% vs. 57%), median PFS (months 8 vs. 7 months) and OS (24 vs. 22 months) were observed between
bortezomib-sensitive and -refractory patients. CarPan proved to be a safe and effective steroid-sparing regimen in a
heavily pre-treated population of MM patients. (Trial registered at ClinicalTrial.gov: NCT01549431)
Key points
● CarPan is a highly active, steroid-sparing regimen, effective in both bortezomib-sensitive and refractory patients.
● The safety profile of CarPan, particularly thrombocytopenia and gastrointestinal adverse events, compares
favorably with that of panobinostat and bortezomib.
Introduction
Multiple myeloma (MM) is a neoplasm characterized by
a clonal proliferation of plasma cells in the bone marrow
and the accumulation of monoclonal protein in serum
and/or urine, with related organ dysfunction. MM is the
second most common hematologic malignancy,
accounting for 10% of all hematologic malignancies and
1% of all cancers1. In the last 15 years, the introduction of
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the first-generation novel agents– the proteasome inhi-
bitor (PI) bortezomib and the immunomodulatory drugs
(IMiDs) thalidomide and lenalidomide– has revolutio-
nized treatment and led to a dramatic improvement in the
survival of MM patients2,3. However, despite the great
efficacy displayed by newer agents, relapse is still inevi-
table and the prognosis of patients relapsing after first-
generation PIs and IMiDs has been shown to be extremely
poor4. This led to the investigation and the approval of
next-generation PIs (carfilzomib, ixazomib) and the IMiD
pomalidomide, as well as agents with novel mechanisms
of action, such as monoclonal antibodies (elotuzumab and
daratumumab) and the histone deacetylase inhibitor
(HDACi) panobinostat.
Carfilzomib, a second-generation PI, is an epoxyketone
that irreversibly binds to the β5 subunit of the protea-
some, preventing protein degradation by the proteasome
itself and thus causing an accumulation of intracellular
proteins that eventually leads to cell death via apoptosis5.
It has significant activity among patients relapsed and/or
refractory (RR) to bortezomib and IMiDs, and has been
approved by American and European regulatory agen-
cies6,7. Currently, carfilzomib is approved with the twice-
weekly schedule at a dose of 27 mg/m2, over a 2- to 10-
min infusion, when given in combination with lenalido-
mide and dexamethasone (KRd), or at a dose of 56 mg/m2,
over a 30-min infusion, when given alone or in combi-
nation with dexamethasone (Kd); nonetheless, other doses
(up to 70mg/m2) and schedules (once versus twice
weekly) have been shown to be promising8,9.
Panobinostat is a pan-HDACi that exerts activity on
class I, II and IV HDACs, thus regulating cell cycle, cell
survival and apoptosis, and intracellular protein home-
ostasis10,11. In a phase II study, panobinostat mono-
therapy showed only modest activity among RRMM
patients12. Both PIs and HDACis can regulate the meta-
bolism on misfolded proteins, leading to their intracellular
accumulation by the dual inhibition of proteasome and
aggresome13. Based on preclinical data showing synergy
between PIs and HDACis, bortezomib and panobinostat
were tested in combination with dexamethasone among
RRMM patients. In the placebo-controlled, phase 3
PANORAMA-1 study conducted among RRMM patients,
the addition of panobinostat to bortezomib and dex-
amethasone (Vd) resulted in a significantly higher rate of
near-complete responses (nCRs) and CRs (28% vs. 16%) as
compared to placebo-Vd, and significantly prolonged
median progression-free survival (PFS, 12 vs. 8 months),
leading to FDA approval for RR patients who have
received at least two prior therapies, including bortezomib
and an IMiD14. Despite a remarkable clinical activity, the
combination of bortezomib and panobinostat was bur-
dened by a significant rate of grade 3/4 thrombocytopenia
(64/67%) and gastrointestinal (GI) toxicity (diarrhea, 20/
25%), more likely due to the overlapping toxicity profiles
of the two anti-myeloma agents14,15.
In this light, to maximize the synergy between panobi-
nostat and PIs, while optimizing the safety profile of the
combination, panobinostat was tested, at different doses
and schedules, with second-generation PIs (carfilzomib
and ixazomib). In a phase 1/2 trial, carfilzomib and
panobinostat (CarPan), the latter administered in a
1 week-on/1 week-off fashion, showed promising efficacy,
67% of heavily pre-treated patients achieving an objective
response, and an acceptable safety profile16.
In order to exploit the synergy between the two drugs,
we tested the administration of carfilzomib and panobi-
nostat, both on a 3-week-on/1-week-off schedule. Herein,
we report the results of a phase 1 study investigating a
steroid-sparing, CarPan doublet regimen, for the treat-
ment of RRMM patients.
Methods
Study population
Patients with relapsed and/or refractory MM who
received at least 1 previous anti-myeloma therapy were
eligible. Patients previously treated with carfilzomib were
excluded from the study. RRMM was defined according to
the International Myeloma Working Group (IMWG)
criteria17. Key inclusion criteria were: age ≥ 18 years;
measurable disease; Eastern Cooperative Oncology Group
performance status of 0 to 2; adequate bone marrow
reserves; serum creatinine clearance ≥ 30 mL per minute;
adequate hepatic function (alanine aminotransferase up to
Table 1 Dose-escalation cohorts
Cohort Carfilzomib (mg/m2)a on days 1, 2, 8, 9, 15, and 16 every 4 weeks Panobinostatb (mg) TIW 3 out of 4 weeks
1 (initial dose level) 27 15
2 27 20
3 36 20
4 45 20
aThe first 2 doses of carfilzomib in cycle 1 were administered at 20 mg/m2 and premedication with dexamethasone 4mg was mandatory prior to each dose of
carfilzomib during cycle 1 and was thereafter administered as clinically indicated
bThree times a week
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2.5 times and bilirubin up to 1.5 times of the upper
normal limit). Exclusion criteria were history or presence
of ventricular arrhythmias; a baseline electrocardiogram
(EKG) with a QTc interval > 450 msec, uncontrolled
hypertension; unstable angina or myocardial infarction
within 6 months prior to enrollment, NYHA Class III or
IV heart failure; impairment of GI function or GI disease
that may significantly alter the absorption of panobino-
stat. The institutional review board at each participating
center approved the study in accordance with the
Declaration of Helsinki. All patients provided written
informed consent. This trial was registered at Clin-
icatrials.gov as NCT01549431.
Study design
This is a multi-center, phase 1 open-label study. In the
dose-escalation portion of the trial, the primary endpoint
was the maximum tolerated dose (MTD) of panobinostat
and carfilzomib when given in combination. Patients were
evaluated for dose-limiting toxicity (DLT) according to
the National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.0. A standard 3+ 3
dose-escalation schedule was used, starting from dose
level 1 with up to 4 sequential dose-escalating cohorts
with 3 to 6 patients in each cohort (Table 1). A DLT was
defined as any treatment-emergent toxicity attributable to
at least 1 of the study drugs occurring during cycle 1.
Non-hematologic DLTs included: ≥ grade 2 cardiac toxi-
city involving either QTc prolongation or congestive heart
failure; any grade ≥ 3 toxicity; any non-hematologic toxi-
city requiring a dose reduction or dose interruption in
cycle 1. Hematologic DLTs included: grade 4 neutropenia
lasting for ≥ 7 days and febrile neutropenia; grade 4
thrombocytopenia associated with bleeding or requiring
more than one platelet transfusion; and a > 7-day delay in
receiving the day-1 dose of cycle 2 due to inadequate
recovery of platelets ( < 75 × 109/L) or other drug-related
toxicity persisting from cycle 1.
In the expansion phase of the trial, 12 additional
patients were enrolled and treated at the MTD of pano-
binostat and carfilzomib to support the secondary objec-
tives of the study including toxicity profile of the
combination; objective response rate (ORR); duration of
response (DOR); PFS and overall survival (OS). In the
exploratory analysis, we evaluated the impact of interna-
tional staging system (ISS), prior exposure to bortezomib
and/or lenalidomide and disease status (refractoriness to
bortezomib) on response rate, PFS and OS.
Study procedures
Salvage treatment with CarPan consisted of 28-day
cycles with twice-weekly carfilzomib (20 mg/m2 intrave-
nously on day 1 and 2 cycle 1, then at a higher dose
Table 2 Patients’ characteristics
n= 32 (%)
Age
Median-years (range) 66 (50–76)
≥ 65 18 (56)
Sex
Female 17 (53)
Male 15 (47)
Ethnicity
Caucasian 19 (59)
African–American 12 (38)
Hispanic 1 (3)
ECOG performance status
0 6 (19)
1 25 (78)
2 1 (3)
MM subtype
IgG 13 (41)
IgA 8 (25)
Light chain 9 (28)
Missing 2 (6)
International staging system
I 18 (56)
II 3 (9)
III 9 (28)
Missing 2 (6)
Bone marrow infiltration
Plasma cells, % median (range) 30 (1–90)
Prior lines of therapy, number
Median, range 4 (1–8)
Prior Bortezomib 29 (91)
- refractory 17 (53)
Prior Lenalidomide 29 (91)
- refractory 10 (31)
Prior pomalidomide 7 (22)
Prior anti-CD38 4 (13)
Prior autologous stem cell transplantation 30 (94)
Disease status at study entry
Relapse and refractory 27 (84)
Relapse 5 (16)
ECOG Eastern Cooperative Oncology Group, MM multiple myeloma, Ig
immunoglobulin, anti-CD38 daratumumab or isatuximab
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according to cohort level on days 8, 9, 15, and 16) and
panobinostat (orally, three times weekly for 3 consecutive
weeks 3 weeks on/1 week off. As a premedication, 4 mg of
dexamethasone was mandatory prior to each dose of
carfilzomib during cycle 1, and then administered as
clinically indicated. Prior to each dose in cycle 1, 250 mL
to 500mL of normal saline or other appropriate IV fluid
was given, as well as additional 250 to 500 mL of IV fluids
as needed following carfilzomib. From cycle 2 onward,
hydration before and after carfilzomib infusion was not
required, unless clinically indicated. Carfilzomib was
administered as an intravenous infusion over 10min at
the dose of 27 mg/m2 and over 30 min for doses ≥ 36mg/
m2. Treatment was continued until progressive disease or
unacceptable toxicities.
Statistical analysis
The sample size of the phase 1 portion was based on the
scenario that cohorts (dose levels 1–4) consisted of 3 to 6
patients. The sample size of the expansion phase was
based on the probability of 53.5% (confidence level) that
the toxicity level of the MTD was within the range of 18 to
33%. All patients who completed at least 1 cycle of the
assigned treatment or discontinued treatment during the
first cycle due to toxicity were evaluable for safety;
patients who started treatment and had at least one on
study anti-myeloma assessment were evaluable for effi-
cacy. Comparisons between different patient groups were
investigated using Fisher’s exact test. Time to response
was calculated from the start of treatment to the date of
the first response (CR, very good partial response [VGPR],
PR, minimal response [MR]). PFS was calculated from
date of entry into the trial to the date of progression or
death or the date the patient was last known to be in
remission. OS was calculated from date of entry into the
trial to the date of death or the date the patient was last
known to be alive. Time-to-event data were analyzed
using the Kaplan–Meier method. The individual effects
on PFS and OS of ISS and disease refractoriness to bor-
tezomib were evaluated using Cox proportional hazards
models. Results are presented as hazard ratios (HRs) and
95% confidence intervals (95% CIs). Data were analyzed
using R software (Version 3.1.1).
Safety and response criteria
All adverse events (AEs) were assessed during each
cycle and graded according to the national Cancer Ter-
minology Criteria for Adverse Events (version 4.0)18.
Responses were recorded at the beginning of every cycle,
according to the IMWG criteria19; MR was defined as a
decrease in the monoclonal component between 25 and
49% from baseline.
Results
Patient characteristics
Between February 2012 and July 2015, 32 RRMM
patients were enrolled at three centers. Patient char-
acteristics are listed in Table 2. The median age at
enrollment was 66 years (range, 50–76 years). The median
number of previous lines of therapy was 4 (range, 1–8),
and the median time from diagnosis to enrollment was 6
years (range, 1–13 years). Twenty-seven patients (84%)
were relapsed and refractory to their last line of treatment.
Twenty-nine patients (91%) had previously received bor-
tezomib; of them, 17 (53%) were bortezomib refractory.
Twenty-nine (91%) patients had previously received
lenalidomide; of them 10 (31%) were refractory. Eight
patients (25%) were double refractory to both bortezomib
and lenalidomide. Thirty out of 32 patients (94%)
underwent a previous autologous stem cell transplant. At
the time of data cut-off for statistical analysis, all patients
had discontinued treatment, mostly due to disease pro-
gression (78%), while 19% of patients stopped treatment
due to the occurrence of AEs.
Maximum tolerated dose
Dose levels and the observed DLTs are listed in Table 3.
Four patients (1 unevaluable due to rapid disease pro-
gression) were enrolled in the first dosing cohort (carfil-
zomib 27mg/m2, panobinostat 15 mg) with no DLT. In
the second cohort, carfilzomib (27 mg/m2) and panobi-
nostat (20 mg), no DLT was reported among the 3
Table 3 Dose-limiting toxicities
Cohort Carfilzomib dose (mg/m2) Panobinostat dose (mg) DLT (no./patients) DLT type
1 27 15 0/4a
2 27 20 0/4b
3 36 20 1/7a - G4 thrombocytopenia and G3 creatinine increase
4 45 20 2/5 - G4 thrombocytopenia—G3 diarrhea
DLT dose-limiting toxicity, G grade
a1 Patient was not evaluable as he did not complete the first cycle due to disease progression
b1 Patient was not evaluable as he did not complete the assigned treatment due to lack of compliance
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patients evaluable (per protocol, 1 patient was not eva-
luable as he did not receive the treatment as planned due
to missed doses not related to AEs). In cohort 3 (carfil-
zomib 36 mg/m2, panobinostat 20 mg), 1 of the 3 patients
enrolled experienced a grade 3 creatinine increase and a
grade 4 thrombocytopenia in cycle 1, necessitating 3
additional enrolled patients, none of whom had a DLT.
Hence, the dose of carfilzomib was escalated. In cohort 4
(carfilzomib 45 mg/m2, panobinostat 20 mg) two DLTs
were observed, a grade 4 thrombocytopenia and a grade 3
diarrhea. The MTD of the combination was then deter-
mined to be carfilzomib 36mg/m2 with panobinostat
20 mg. An additional 12 patients were enrolled at the
MTD, for a total of 18 patients at this dose level; of them,
16 were evaluable for efficacy.
Safety
Treatment-related AEs are listed in Table 4. Per pro-
tocol, 30 patients were evaluable for toxicities. Eleven
patients (37%) had at least 1 treatment-related serious
adverse event (SAE). Any grade hematological treatment-
related AEs occurred in 29 of 30 patients (97%), while
grade 3/4 hematological AEs occurred in 19 (63%)
patients, including thrombocytopenia in 14 (47%), anemia
in 9 (30%) and neutropenia in 6 (20%) patients. Any grade
non-hematological treatment-emergent AEs were
observed in 28 (93%) patients; grade 3/4 non-
hematological AEs were reported in 17 (57%) patients,
and the most frequent were gastrointestinal events, with
nausea and vomiting, diarrhea and anorexia in 7% of
patients each, fatigue (17%), and hypophosphatemia
(10%). Any grade and grade 3–4 cardiac AEs occurred in 6
(20%) and 1 (3%) patients, respectively. One grade 5 AE
(cardiac arrest) was observed during cycle 2 (cohort 1) in a
patient with no cardiovascular comorbidities, a normal
Table 4 Treatment-related adverse events (≥5% of the
patients)
Events, n (%) All patients (n = 30) MTD (n = 17)
Any
grade
Grade 3–5 Any
grade
Grade 3–5
Hematologic
≥ 1 event 29 (97) 19 (63) 12 (71) 10 (59)
Anemia 12 (40) 9 (30) 5 (29) 3 (18)
Thrombocytopenia 16 (53) 6 (47) 7 (41) 7 (41)
Neutropenia 6 (20) 6 (20) 2 (12) 2 (12)
Non-hematologic
≥ 1 event 28 (94) 17 (57) 16 (94) 10 (59)
Gastrointestinal ( ≥ 1
event)
26 (87) 7 (23) 14 (82) 5 (29)
Nausea/Vomiting 22 (73) 2 (7) 12 (71) 2 (12)
Diarrhea 17 (57) 2 (7) 8 (47) 1 (6)
Anorexia 8 (27) 2 (7) 5 (29) 1 (6)
Dysgeusia 3 (10) – 2 (12) –
Dyspepsia 2 (7) 1 (3) 2 (12) 1 (6)
General ( ≥ 1 event) 17 (57) 5 (17) 11 (64) 3 (18)
Fatigue 15 (50) 5 (17) 10 (59) 3 (18)
Fever 7 (23) – 3 (18) –
Weight loss 2 (7) – 1 (6) –
Neurological ( ≥ 1 event) 14 (47) – 6 (35) –
Insomnia 6 (20) – 4 (24) –
Neuropathy, sensitive 3 (10) – – –
Headache 3 (10) – 2 (12) –
Dizziness 3 (10) – – –
Cramps 2 (7) – 1 (6) –
Vascular ( ≥ 1 event) 7 (23) 2 (7) 4 (24) 1 (6)
Hypertension 7 (23) 2 (7) 3 (18) 1 (6)
Phlebitis 3 (10) – 2 (12) –
Cardiac ( ≥ 1 event) 6 (20) 2 (7) 3 (18) 1 (6)
Arrhythmias 5 (17) – 2 (12) –
Renal ( ≥ 1 event) 5 (17) 2 (7) 2 (12) 1 (6)
Creatinine increase 5 (17) 2 (7) 2 (12) 1 (6)
Pulmonary ( ≥ 1 event) 3 (10) – 1 (6) 1 (6)
Dyspnea 3 (10) – 1 (6) 1 (6)
Hepatic ( ≥ 1 event) 3 (10) – 3 (18) –
Bilirubin increase 2 (7) – 2 (12) –
Infection ( ≥ 1 event) 2 (7) – – –
Table 4 continued
Events, n (%) All patients (n = 30) MTD (n = 17)
Any
grade
Grade 3–5 Any
grade
Grade 3–5
Dermatological ( ≥ 1
event)
2 (7) – 2 (12) –
Rash 2 (7) – 2 (12) –
Other
Hypokalemia 4 (13) – 4 (24) –
Hypophosphatemia 5 (17) 2 (7) 2 (12) 1 (6)
Peripheral edema 3 (10) – 4 (24) –
Hypocalcemia 2 (7) 1 (3) – –
Percentage may not total 100% due to rounding
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baseline EKG and no significant EKG alterations,
including QT prolongation, study during treatment, and
normal echocardiogram study; this event was attributed to
be study related. Patients were monitored with EKG
during treatment: in 4 (13%) patients a prolongation in
the QT interval was registered during routine EKG,
however only 1 event was reported as a grade 1 AE (3%).
Any grade and grade 3/4 hypertension were observed in 7
(23%) and 2 (5%) patients.
A low rate of any grade peripheral neuropathy was
reported (10%), without any grade 3–4 events. At least 1
dose reduction of carfilzomib was necessary in 7 patients
(23%) while the dose of panobinostat was reduced in 13
patients (43%). AEs leading to treatment discontinuation
were thrombocytopenia (n= 2), acute pancreatitis (n= 1),
cardiac arrest (n= 1), bowel perforation (n= 1), and
congestive heart failure (n= 1).
Efficacy
Per protocol, 30 patients were evaluable for efficacy
(Table 5). Patients received a median of 8 cycles (range,
1–23 cycles) of study treatment. The ORR in the overall
population was 57%; 10 patients achieved PR (33%), 5
VGPR (17%), and 2 CR (7%). Taking into account 4
patients who had a MR (13%), the clinical benefit rate
(CBR) was 70%. Among patients treated at the MTD of
carfilzomib and panobinostat the ORR was 63%, and 25%
of patients achieved VGPR or better. The median time to
at least PR was 2 months, and the median duration of
response was 9 months. No differences were observed
among bortezomib refractory and bortezomib-sensitive
patients in terms of ORR (57% vs. 55%; p= 1) and at least
VGPR rate (25% vs. 18%; p= 1). Moreover, in patients
previously exposed to both bortezomib and lenalidomide,
CarPan was able to induce an objective response in 48% of
them, with a CBR rate of 65%.
No differences in ORR and at least VGPR rate were
reported among patients with ISS 1 (56% and 61%,
respectively) or ISS 2–3 (50% and 67%, respectively). After
a median follow-up of 27 months, median PFS and OS in
Table 5 Best response with carfilzomib and panobinostat in the overall population
Best
response
All MTD Bortezomib
sensitive
Bortezomib refractory Prior bortezomib and
lenalidomide
Lenalidomide
refractory
Bortezomib and
lenalidomide refractory
n = 30 n = 16 n = 11 n = 16 n = 23 n = 8 n = 7
(%) (%) (%) (%) (%) (%) (%)
CR 2 (7) 1 (6) 1 (3) 1 (3) 2 (9) – –
VGPR 5 (17) 3 (19) 1 (3) 3 (10) 2 (9) 1 (13%) –
≥ VGPR 7 (23) 4 (25) 2 (7) 4 (13) 4 (17) 1 (13%) –
PR 10 (33) 6 (38) 4 (13) 5 (17) 7(30) 3 (38%) 3 (43%)
MR 4 (13) 1 (6) 2 (7) 2 (7) 4 (17) 1 (13%) 1 (14%)
SD 4 (13) 3 (19) – 4 (13) 4 (7) 2 (25%) 2 (29%)
PD 5 (17) 2 (13) 3 (10) 1 (3) 4 (3) 1 (13%) 1 (14%)
ORR 17 (57) 10 (63) 6 (55) 9 (57) 11 (48) 4 (50%) 3 (43%)
CBR 21 (70) 11 (68) 8 (73) 11 (69) 15 (65) 5 (63%) 4 (57%)
Percentage may not total 100% due to rounding
MTD maximum tolerated dose, CR complete response, VGPR very good partial response, PR partial response, MR minimal response, SD stable disease, PD progression
disease, ORR objective response rate, CBR clinical benefit rate
Fig. 1 Time-to-event analysis. Kaplan–Meier progression-free
survival (a) and overall survival (b) curves
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the overall population were 8 (95% CI: 5–11 months) and
23 months (95% CI: 16-NA months) (Fig. 1). No differ-
ences in median PFS (7 vs. 8 months; HR: 1.3, p= 0.5) and
OS (22 vs. 24 months; HR1.8, p= 0.2) were noted
between bortezomib refractory and sensitive patients, as
well as between median PFS (8 vs. 7 months; HR: 1.9, p=
0.1) and OS (24 vs. 22 months; HR: 1.9, p= 0.15) in
patients with ISS 1 as compared with ISS 2 or 3 disease.
Discussion
In this phase 1 study, the MTD of the CarPan regimen
was panobinostat 20 mg, administered 3 times weekly in a
3-week-on/1-week-off schedule, in combination with
twice-weekly carfilzomib at the dose of 36 mg/m2. The
most common AEs were hematological, mainly throm-
bocytopenia, and GI, including nausea, vomiting and
diarrhea. In a heavily pre-treated population, in which
patients have received a median of 4 prior lines of
therapies and 84% of patients were relapsed and refractory
to their last line of treatment, the MTD of CarPan showed
promising results in terms of ORR (63%) and PFS (med-
ian, 8 months). Based on preclinical studies showing
synergism between HDACis and PI (mediated by a double
blockade of the intracellular protein degradation system)
and evidence of a modest anti-myeloma activity displayed
by single agent panobinostat, the combination of pano-
binostat and Vd has been tested12,13. The phase 2
PANORAMA-2 trial tested panobinostat, 20 mg in a 2-
week-on/1-week-off schedule, with Vd in a bortezomib
refractory population15. The addition of panobinostat to
Vd was able to re-capture an objective response in 35% of
the patients. Despite the evident clinical activity,
panobinostat-Vd also showed a significant toxicity profile,
mainly consisting of thrombocytopenia (grade 3–4, 64%),
GI AEs such as diarrhea (grade 3–4, 20%), and fatigue
(grade 3–4, 20%). Similar results were confirmed by the
phase 3 PANORAMA-114.
Carfilzomib is a second generation PI with significant
activity, even among bortezomib exposed patients, that
has been combined with panobinostat, at different doses
and schedules, in early phase trials (NCT01301807,
NCT01549431, NCT01496118)20. We tested escalating
doses of panobinostat (up to 20mg) administered 3 times
a week in a 3-week-on/1-week-off schedule, to fit with the
standard schedule of carfilzomib (twice weekly, 3 weeks
on/1 week off) and maximize the synergy between pro-
teasome and HDAC inhibition. Three out of 4 DLTs were
hematological (grade 4 thrombocytopenia, n= 2) and GI
(grade 3 diarrhea, n= 1) in nature. Thrombocytopenia is a
well-known HDACi class-effect, due to the inhibition of
maturation of megakaryocytes and the release of pro-
platelets. It has been shown that it rapidly reverses with-
holding the drug; hence, it is possible that a different
schedule might allow higher dose of panobinostat and
Table 6 Panobinostat-based combination in relapsed/refractory multiple myeloma patients
Carfilzomib-
panobinostat
Kaufman
Carfilzomib-
panobinostat
Berdeja6,23
Panobinostat-bortezomib-
dexamethasone San-
Miguel14
Panobinostat-lenalidomide-
dexamethasone Chari25
Panobinostat schedule 20 mg TIW, 3 weeks on/
1 week off
30 mg TIW, 1 week on/
1 week off
20 mg TIW, 2 weeks on/1 week
off
20 mg TIW, 3 weeks on/1 week
off
Prior regimens, no. 4 5 5 3
Bortezomib refractory patients 53% 36% 100% 52%
Lenalidomide refractory
patients
31% 14%a NA 81%
Bortezomib and lenalidomide
refractory patients
25% NA NA NA
ORR 63% 63% 34.5% 41%
PFS 8 8 5 7
Thrombocytopenia G3–4 41% 38% 64% 31%
Fatigue G3–4 18% 11% 20% 15%
Diarrhea G3–4 6% 11% 20% 11%
Nausea/vomiting G3–4 12% 21% 18% 0%
Discontinuation for toxicity 19% 11% 18% NA
Dose reduction for toxicity 43% 59% 65% 41%
aIMiDs (thalidomide or lenalidomide) refractory
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carfilzomib21,22. In a phase 1/2 trial published by Berdeja
et al.16, standard twice-weekly carfilzomib was combined
with panobinostat, 3 times a week, administered every
other week (1-week-on/1-week-off), in 4 weeks cycles. No
DLTs were observed up to a dose of 30 mg for panobi-
nostat and 45mg/m2 for carfilzomib. Despite the fact that
the MTD was not reached during the dose-escalation,
59% of patients in the expansion phase required dose
reductions for panobinostat, and the average dose of
panobinostat delivered was 23.6 mg. A second dose
expansion phase was presented by Berdeja et al., with
panobinostat at a dose of 20 mg (1-week-on/1-week-off)
and carfilzomib at 56 mg/m2,23. Despite a toxicity profile
similar to that observed in the previous cohorts, dose
reductions were required for 48% of patients receiving
carfilzomib and for 64% of patients receiving panobino-
stat; therefore, the average doses of carfilzomib and
panobinostat were 48mg/m2 and 14.7 mg, respectively.
The safety profile of CarPan in our trial is consistent
with that reported by Berdeja et al., and better than the
safety profile exhibited by panobinostat-Vd in the
PANORAMA-2 trial in the rates of grade 3–4 thrombo-
cytopenia (41% vs. 64%), diarrhea (6% vs. 20%) and fatigue
(18% vs. 20%) (Table 6). The rate of grade 3–4 treatment-
related hypertension in our trial was 7%, consistent with
previous experience with carfilzomib when combined
with dexamethasone, panobinostat, lenalidomide, and
pomalidomide8,16,20,24. Patients were extensively mon-
itored with serial EKGs during the trial: in 4 patients a QT
prolongation was observed; however, only in 1 patient this
was considered clinically significant and reported as an
AE (grade 1). As expected, peripheral neuropathy occur-
red at a very low rate (any grade, 10%), without any ser-
ious (grade 3/4) AEs.
In our trial, the ORR at the MTD of CarPan (63%)
compares favorably with the ORR reported with
panobinostat-Vd in the PANORAMA-2 study (34.5%) and
even in the PANORAMA-1 study (61%), which enrolled a
less heavily pre-treated population (median number of
prior lines of 1). In fact, our trial enrolled patients with a
median of 4 prior therapies, half of them being bortezo-
mib refractory14,15. CarPan was effective not only among
bortezomib-sensitive patients (ORR: 55%; CBR: 73%), but
also among bortezomib refractory patients (ORR: 57%;
CBR: 69%). Of note, these results were obtained in a
steroid-sparing regimen. The efficacy displayed by CarPan
is consistent with that reported by Berdeja et al., in terms
of ORR (63% vs. 72% in patients treated at the MTD) and
median PFS (8 vs. 8 months); of note, in our trial 84% of
patients were relapsed and refractory to their last regimen,
a significantly higher proportion as compared to that
reported by Berdeja et al. (36%)16.
In conclusion, we confirmed that the combination of
the second-generation PI carfilzomib with panobinostat,
in a two-drug, steroid-sparing regimen, is a safe and
effective treatment option for RRMM patients. Future
trials should compare different doses and schedules of the
combination in order to optimize the treatment toler-
ability and enhance its efficacy.
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